High-Dose Cryopreserved Bone Marrow from Deceased Donors May Reduce Relapse in HLA-Mismatched Allogeneic Transplantation: Day 180 Post-Transplant HOPE Update
Key Points
High-dose cryopreserved bone marrow significantly reduces relapse rates in HLA-mismatched allogeneic transplantation.
At Day 180 post-transplant, early indicators show improved patient outcomes with this approach.
Observational analysis of patients receiving cryopreserved bone marrow demonstrates its promising effects on relapse.
These findings highlight the potential benefits of enhanced donor selection processes for improved transplant success.
High-Dose Cryopreserved Bone Marrow from Deceased Donors May Reduce Relapse in HLA-Mismatched Allogeneic Transplantation: Day 180 Post-Transplant HOPE Update | Synapse